| gmx_MMPBSA: a new tool to perform end-state free energy calculations with GROMACS MS Valdés-Tresanco, ME Valdés-Tresanco, PA Valiente, E Moreno Journal of chemical theory and computation 17 (10), 6281-6291, 2021 | 975 | 2021 |
| Humanized and chimeric monoclonal antibodies that recognize epidermal growth factor receptor (EGF-R); diagnostic and therapeutic use C Mateo de Acosta, R Perez Rodriguez, E Moreno Frias US Patent 5,891,996, 1999 | 440* | 1999 |
| Humanization of a mouse monoclonal antibody that blocks the epidermal growth factor receptor: recovery of antagonistic activity C Mateo, E Moreno, K Amour, J Lombardero, W Harris Immunotechnology 3 (1), 71-81, 1997 | 296 | 1997 |
| Neutralizing interaction between heparins and myotoxin II, a lysine 49 phospholipase A2 from Bothrops asper snake venom. Identification of a heparin-binding and cytolytic toxin … B Lomonte, E Moreno, A Tarkowski, LA Hanson, M Maccarana Journal of Biological Chemistry 269 (47), 29867-29873, 1994 | 267 | 1994 |
| Nimotuzumab, an antitumor antibody that targets the epidermal growth factor receptor, blocks ligand binding while permitting the active receptor conformation A Talavera, R Friemann, S Gómez-Puerta, C Martinez-Fleites, G Garrido, ... Cancer research 69 (14), 5851-5859, 2009 | 255 | 2009 |
| AMDock: a versatile graphical tool for assisting molecular docking with Autodock Vina and Autodock4 MS Valdés-Tresanco, ME Valdés-Tresanco, PA Valiente, E Moreno Biology direct 15, 1-12, 2020 | 187 | 2020 |
| Human IL-2 mutein with higher antitumor efficacy than wild type IL-2 T Carmenate, A Pacios, M Enamorado, E Moreno, K Garcia-Martínez, ... The Journal of Immunology 190 (12), 6230-6238, 2013 | 139 | 2013 |
| Removal of amphipathic epitopes from genetically engineered antibodies: production of modified immunoglobulins with reduced immunogenicity C Mateo, J Lombardero, E Moreno, A Morales, G Bombino, J Coloma, ... Hybridoma 19 (6), 463-471, 2000 | 124 | 2000 |
| Light-chain shuffling results in successful phage display selection of functional prokaryotic-expressed antibody fragments to N-glycolyl GM3 ganglioside G Rojas, A Talavera, Y Munoz, E Rengifo, U Krengel, J Ångström, ... Journal of immunological methods 293 (1-2), 71-83, 2004 | 68 | 2004 |
| Structure and molecular interactions of a unique antitumor antibody specific for N-glycolyl GM3 U Krengel, LL Olsson, C Martínez, A Talavera, G Rojas, E Mier, ... Journal of Biological Chemistry 279 (7), 5597-5603, 2004 | 61 | 2004 |
| Delineation of the epitope recognized by an antibody specific for N-glycolylneuraminic acid—containing gangliosides E Moreno, B Lanne, AM Vázquez, I Kawashima, T Tai, LE Fernández, ... Glycobiology 8 (7), 695-705, 1998 | 56 | 1998 |
| A view on EGFR-targeted therapies from the oncogene-addiction perspective R Perez, T Crombet, J Leon, E Moreno Frontiers in pharmacology 4, 53, 2013 | 54 | 2013 |
| EGFR-targeting as a biological therapy: understanding nimotuzumab’s clinical effects R Perez, E Moreno, G Garrido, T Crombet Cancers 3 (2), 2014-2031, 2011 | 54 | 2011 |
| Therapeutic targeting of CD6 in autoimmune diseases: a review of cuban clinical studies with the antibodies IOR-T1 and itolizumab P Hernández, E Moreno, L E Aira, P C Rodríguez Current drug targets 17 (6), 666-677, 2016 | 49 | 2016 |
| Nimotuzumab and cetuximab block ligand-independent EGF receptor signaling efficiently at different concentrations C Berger, U Krengel, E Stang, E Moreno, IH Madshus Journal of Immunotherapy 34 (7), 550-555, 2011 | 49 | 2011 |
| Blocking IL-2 signal in vivo with an IL-2 antagonist reduces tumor growth through the control of regulatory T cells T Carmenate, Y Ortíz, M Enamorado, K García-Martínez, J Avellanet, ... The Journal of Immunology 200 (10), 3475-3484, 2018 | 43 | 2018 |
| Redefinition of the carbohydrate specificity of Erythrina corallodendron lectin based on solid-phase binding assays and molecular modeling of native and recombinant forms … E Moreno, S Teneberg, R Adar, N Sharon, KA Karlsson, J Ångström Biochemistry 36 (15), 4429-4437, 1997 | 43 | 1997 |
| A shift from N-glycolyl- to N-acetyl-sialic acid in the GM3 ganglioside impairs tumor development in mouse lymphocytic leukemia cells AV Casadesús, Y Fernández-Marrero, M Clavell, JA Gómez, T Hernández, ... Glycoconjugate journal 30, 687-699, 2013 | 39 | 2013 |
| Structural insights into the design of synthetic nanobody libraries MS Valdés-Tresanco, A Molina-Zapata, AG Pose, E Moreno Molecules 27 (7), 2198, 2022 | 36 | 2022 |
| Crystal structure of an anti-ganglioside antibody, and modelling of the functional mimicry of its NeuGc-GM3 antigen by an anti-idiotypic antibody A Talavera, A Eriksson, M Ökvist, A López-Requena, ... Molecular Immunology 46 (16), 3466-3475, 2009 | 35 | 2009 |
Mario E. Valdés-TresancoCentre for Molecular Simulations, University of Calgary在 ucalgary.ca 的电子邮件经过验证
